Helicobacter pylori infection
Conditions
Interventions
Control group:Cefuroxime 500mg bid + Levofloxacin 500mg qd + Vonolasan 20mg bid + Bismuth potassium citrate 220mg bid for 14 days.
Experimental group :Cefuroxime 500mg tid + Vonolasan 20mg bid for 14 days.
Sponsors
Tongji Medical College, Huazhong University of Science and Technology/ Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients, aged 18-65 years; 2. H. pylori infection was diagnosed by C13/ C14-urea breath test; 3. With H. pylori eradicating indications, without counterbalance factors; 4. Did not receive H. pylori eradication therapy; 5. No antibiotics, bismuth and antibacterial active Chinese medicine were taken 4 weeks before treatment; In the first 2 weeks, no Vonorosine, PPI or non-steroidal anti-inflammatory drugs were taken; 6. Patients were informed and consented to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, liver, lung and renal insufficiency and low immunity (such as HIV infection and moderate cancer treatment); 2. Patients with allergy contraindications of cefuroxime, levofloxacin or related drugs in the regimen; 3. Patients with mental illness or communication disorder; 4. Pregnancy and lactation; 5. Complicated with severe digestive tract diseases, such as tumors, digestive tract bleeding, and Zhuo-Ai syndrome; 6. Participating in other clinical trials; 7. Those who were considered unsuitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Compliance; | — |
Countries
China
Contacts
Public ContactLi Peiyuan
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed